Caroline Sindet-Pedersen, ESC 2022: SARS-CoV-2 mRNA vaccines in patients with heart failure
Studies investigating the safety and efficacy of the severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) mRNA vaccines lacked representation of patients with heart failure. In this touchCARDIO interview, we speak with Dr Caroline Sindet-Pedersen (Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark) to discuss the study presented at ESC 2022 that aimed to investigate the risk of worsening heart failure and all-cause mortality associated with the SARS-CoV-2 mRNA vaccines in a Danish nationwide cohort of patients with heart failure.
The abstract entitled ‘COVID mRNA vaccines are safe in patients with heart failure’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What is known about the risks of adverse COVID-19 outcomes in heart failure patients? (0:17)
- What are the common perceptions of cardiovascular side effects from mRNA vaccinations and what evidence supports these perceptions? (0:48)
- What were the aims, design and patient population of the study you are presenting? (1:31)
- How did the risks of adverse outcomes compare in the two groups? (2:38)
- What is the key take-home message of these findings? (3:21)
Disclosures: Caroline Sindet-Pedersen has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on COVID-19 here and Heart Failure here
Share this Video
Related Videos In Heart Failure
John Boehmer, ACC 2023: The MicrocorTM device for heart failure management, the BMAD trial
Rates of readmission following heart failure hospitalization are high. The BMAD trial in patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Barry Borlaug, ACC 2023: Dapagliflozin in heart failure, an invasive hemodynamic randomized trial
Heart failure with preserved ejection fraction (HFpEF) is a hemodynamic disorder characterized by an elevation of left ventricular filling pressures. This trial assessed the ability of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), to reduce this elevation. In this touchCARDIO interview, we speak with Dr Barry Borlaug (Mayo Clinic, Rochester, MN, USA) to discuss the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!